PriceTargets.com logo

Boundless Bio - BOLD Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.89 As of 09/2/2026 10:40 AM ET
▼ -0.002 (-0.07%)

This chart shows the closing price for BOLD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Boundless Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BOLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BOLD

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Boundless Bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.89.

This chart shows the closing price for BOLD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 2 contributing investment analysts is to sell stock in Boundless Bio. This rating changed within the last month from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/11/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/6/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/4/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
8/3/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
9/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/29/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/23/2026UBS GroupInitiated CoverageReduce
5/1/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
3/27/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/15/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/11/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/5/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/28/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/11/2025HC WainwrightLower TargetBuy ➝ Buy$5.00 ➝ $4.00
6/2/2025HC WainwrightInitiated CoverageBuy$5.00
5/28/2025Leerink PartnersDowngradeOutperform ➝ Market Perform$15.00 ➝ $3.00
5/27/2025Leerink PartnersDowngradeStrong-Buy ➝ Hold
12/13/2024GuggenheimDowngradeBuy ➝ Neutral
4/22/2024Piper SandlerInitiated CoverageOverweight$20.00
4/22/2024GuggenheimInitiated CoverageBuy$24.00
4/22/2024Leerink PartnersInitiated CoverageOutperform$25.00
(Data available from 9/2/2021 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/4/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/6/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/5/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/5/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/4/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/4/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/3/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/2/2026

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Boundless Bio logo
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
Read More

Today's Range

Now: $2.89
Low: $2.81
High: $2.91

50 Day Range

MA: $2.64
Low: $2.41
High: $3.00

52 Week Range

Now: $2.89
Low: $0.96
High: $3.16

Volume

145,928 shs

Average Volume

234,796 shs

Market Capitalization

$65.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Boundless Bio?

The following Wall Street sell-side analysts have issued reports on Boundless Bio in the last twelve months: UBS Group AG, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for BOLD.

What is the current price target for Boundless Bio?

0 Wall Street analysts have set twelve-month price targets for Boundless Bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Boundless Bio in the next year.
View the latest price targets for BOLD.

What is the current consensus analyst rating for Boundless Bio?

Boundless Bio currently has 2 sell ratings from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe BOLD will underperform the market and that investors should sell shares of Boundless Bio.
View the latest ratings for BOLD.

What other companies compete with Boundless Bio?

Other companies that are similar to Boundless Bio include CAMP4 Therapeutics, MacroGenics, Akebia Therapeutics, ProQR Therapeutics and Avidity Biosciences. Learn More about companies similar to Boundless Bio.

How do I contact Boundless Bio's investor relations team?

Boundless Bio's physical mailing address is 10955 ALEXANDRIA WAY, SAN DIEGO, CA 92121. The biotechnology company's listed phone number is (858) 766-9912 and its investor relations email address is [email protected]. The official website for Boundless Bio is www.boundlessbio.com. Learn More about contacing Boundless Bio investor relations.